Zai Lab announces first patient treated in Greater China in PANOVA-3 phase III pivotal trial.
PANOVA-3 is a global, open-label, randomized Phase III trial evaluating the efficacy of Tumor Treating Fields administered concomitantly with gemcitabine and nab-paclitaxel as front-line treatment for patients with unresectable, locally advanced pancreatic cancer. The trial is expected to enroll approximately 556 patients. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, resectability rate, and toxicity.
Related news and insights
Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies